Market Challenges And Opportunities

Periodontal Disease Therapeutics Market Drivers

Oral care and dental hygiene are one of the major concerns worldwide. High prevalence of periodontal disease is propelling demand for oral treatment. Periodontal disease is a result of various risk factors, such as aging, smoking, poor oral hygiene, heredity, stress, and other medical conditions.

Periodontal disease are majorly observed in adults. According to the Centre for Disease Control and Prevention (CDC), in 2018, the prevalence of periodontitis has been estimated to be over 50% in U.S. adults aged 30 years and older i.e. 64.7 million Americans. Among those adults, 8.7% showed mild disease, 30% demonstrated moderate disease, 8.5% had severe chronic periodontitis. Disease prevalence increases with age, with 70% adults, who are 65 years and above, suffering from periodontitis. There are many environmental risk factors that are associated with inflammatory responses, which include smoking, diabetes mellitus, and poor health habits driving the chronic inflammatory response in periodontitis, and are beneficial for the periodontitis disease therapeutic market.

Also, advancements in treatment by using novel drugs is expected to fuel the periodontal disease therapeutics market growth. For instance, in January 2017, ST266 by Noveome Biotherapeutics, Inc., is an expected candidate for disease treatment, which is currently in phase I clinical trials. ST266, is used to treat patients with moderate to severe periodontitis. It provide essential tools at critical stages of the healing process to restore homeostasis within the periodontal microenvironment.

Local antibiotics for the treatment of periodontal disease to present more growth opportunities in the periodontal disease therapeutics market. Increasing preference for controlled local drug delivery approaches over systemic drug delivery due to better therapeutic outcomes by achieving factors such as site specific delivery, low dose requirement, reduces side effects favors the growth of local antibiotics. Furthermore, it provide safe and effective mode of treatment and is expected to lead the market in the next few years due to various advantages. Systemic antibiotics is expected to hold dominance in global market due to factors such as product affordability, availability, and high market penetration. Growing number of preventive care for dental and gum problems and poor reimbursement policies in many economies are hindering the growth of periodontal disease therapeutic market.